Spectranetics Corporation   Report issue

For profit Phase 2
Founded: Colorado Springs CO United States (1984)
Status: No NME R&D (1984)

Organization Overview

First Clinical Trial
2012
NCT01599078
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Spectranetics Corporation

Active Ingredients

Drugs in Phase 2 Trials (1)

paclitaxel (taxol) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Constriction, Pathologic (Phase 2)

Fistula (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1